XLO Q1 2025 Earnings — Xilio Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

XLOXilio Therapeutics, Inc.

$28M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M

Gross Profit

$3M100.0% margin

Operating Income

-$14M-472.7% margin

Net Income

-$13M-452.7% margin

EPS (Diluted)

$-0.18

QoQ Revenue Growth

+70.0%

Cash Flow

Operating Cash Flow

$29M

Free Cash Flow

$29M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$104M

Total Liabilities

$93M

Stockholders' Equity

$11M

Cash & Equivalents

$89M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$0	—
Gross Profit	$3M	$0	—
Operating Income	-$14M	-$17M	+20.8%
Net Income	-$13M	-$17M	+22.9%